Skip to main content
. 2021 Aug 25;9(4):264–276.

Figure 3.

Figure 3

EPLIN is a molecular target of genistein in metastatic PCa cells. A. Genistein inhibits the in vitro invasion in transwell experiments (18 h) and increases the in vitro adhesion on fibronectin-coated plates (6 h) in ARCaPE and ARCaPM cells. B. Genistein treatment (48 h) induces EPLIN-β mRNA in PC-3 and ARCaPM cells, as determined by qRT-PCR. C. Genistein activates the human EPLIN-β promoter in a dose-dependent manner (48 h). D. Genistein dose-dependently induces EPLIN protein expression (72 h). E. Genistein (50 mg/kg, intraperitoneal injection, 4 times per week, 4-week treatment) increases EPLIN and E-cadherin in C4-2 subcutaneous tumors (n = 6 per group). Refer to Supplementary Information.